A recent modeling study has identified risk factors predictive of good and bad outcomes in non-diabetic CKD, such as gender, ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which ...

A retired Chicago firefighter who was honored by the state for the lives he saved during his 30-year career is now in desperate need of a kidney.

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...